drugset / Trial / NCT06469411
Effect of PMSCs and Their Secretome for the Treatment of GvHD
Phase 3
Completed
60 enrolled
Tabriz University of Medical Sciences
SCARM Institute, Tabriz, Iran · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In this clinical trial study, 60 patients with GvHD referred to Shahid Qazi Hospital in Tabriz, were randomly divided into 2 intervention and control groups (n= 30 in each) that received secretome and distilled water by injection, respectively. The method of blinding was triple-blinded and all the names and personal information of the patients were coded at the time of data collection and remained completely confidential.
Timeline
- Start
- 2023-01-01
- Primary completion
- 2023-06-30
- Completion
- 2024-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secretome | Other / unclassified | 4 ml | Intravenous |